Abstract:Non-alcoholic fatty liver disease (NAFLD) is a major health care problem and represents the hepatic expression of the metabolic syndrome. NAFLD is classified as non-alcoholic fatty liver (NAFL) or simple steatosis, and non-alcoholic steatohepatitis (NASH). NASH is characterized by the presence of steatosis and inflammation with or without fibrosis. The physiopathology of NAFL and NASH and their progression to cirrhosis involve several parallel and interrelated mechanisms, such as, insulin resistance (IR), lipotoxicity, inflammation, oxidative stress, and recently the gut-liver axis interaction has been described. Incretin-based therapies could play a role in the treatment of NAFLD. Glucagon-like peptide-1 (GLP-1) is an intestinal mucosa-derived hormone which is secreted into the bloodstream in response to nutrient ingestion; it favors glucose-stimulated insulin secretion, inhibition of postprandial glucagon secretion and delayed gastric emptying. It also promotes weight loss and is involved in lipid metabolism. Once secreted, GLP-1 is quickly degraded by dipeptidyl peptidase-4 (DPP-4). Therefore, DPP-4 inhibitors are able to extend the activity of GLP-1. Currently, GLP-1 agonists and DPP-4 inhibitors represent attractive options for the treatment of NAFLD and NASH. The modulation of lipid and glucose metabolism through nuclear receptors, such as the farsenoid X receptor, also constitutes an attractive therapeutic target. Obeticholic acid is a potent activator of the farnesoid X nuclear receptor and reduces liver fat content and fibrosis in animal models. Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid with immunomodulatory, anti-inflammatory, antiapoptotic, antioxidant and anti-fibrotic properties. UDCA can improve IR and modulate lipid metabolism through its interaction with nuclear receptors such as, TGR5, farnesoid X receptor-α, or the small heterodimeric partner. Finally, pharmacologic modulation of the gut microbiota could have a role in the therapy of NAFLD and NASH. Probiotics prevent bacterial translocation and epithelial invasion, inhibit mucosal adherence by bacteria, and stimulate host immunity. In animal models, probiotics prevent obesity, decrease transaminase levels, and improve IR and liver histology in NASH.

Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease

Mechanisms and therapeutic implications of selective autophagy in nonalcoholic fatty liver disease

Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics

Lipophagy: Molecular Mechanisms and Implications in Hepatic Lipid Metabolism

Research Progress on Lipophagy-Mediated Exercise Intervention in Non-Alcoholic Fatty Liver Disease

Endoplasmic Reticulum Stress and Lipophagy in Nonalcoholic Steatohepatitis

Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review

The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy

Involvement of Lipophagy and Chaperone-Mediated Autophagy in the Pathogenesis of Non-Alcoholic Fatty Liver Disease by Regulation of Lipid Droplets

Autophagy: A Cellular Guardian against Hepatic Lipotoxicity

Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

Targeting Autophagy for the Treatment of Liver Diseases

The Regulation of TFEB in Lipid Homeostasis of Non-Alcoholic Fatty Liver Disease: Molecular Mechanism and Promising Therapeutic Targets

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease

Targeting cell death in NAFLD: mechanisms and targeted therapies

Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis